Welcome to our dedicated page for Bausch + Lomb Corporation SEC filings (Ticker: BLCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bausch + Lomb Corporation filings document the reporting obligations of a Canada-incorporated eye health company whose common shares trade on the New York Stock Exchange and Toronto Stock Exchange under BLCO. Its 8-K reports cover quarterly and annual operating results, non-GAAP financial measures, guidance, investor presentations, material credit-agreement amendments and refinancing activity.
Proxy materials describe annual shareholder meeting matters, board composition, director independence, committee assignments and executive compensation governance. Other event filings record board appointments, committee changes, registered common-share details and Regulation FD disclosures tied to the company's product pipeline, Pharmaceuticals, Surgical and Vision Care operations.
Bausch & Lomb Corp executive Luc Bonnefoy reported a routine tax-withholding transaction related to equity compensation. On the vesting of restricted share units, 1,008 common shares were withheld at an indicated value of $15.08 per share to satisfy tax obligations. After this non-market disposition, Bonnefoy directly holds 87,023 common shares.
VON ESCHENBACH ANDREW C. reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp director Andrew C. Von Eschenbach received an annual equity grant of 15,842 common shares, reported as a grant or award at $15.78 per share. The award reflects restricted share units granted under the company’s 2022 Omnibus Incentive Plan and is scheduled to vest before the next annual shareholder meeting, bringing his direct holdings to 86,656 common shares.
Bausch & Lomb Corporation director Ross Thomas W. Sr. reported an acquisition of 15,842 common shares tied to a new equity award. The filing shows this as a grant of restricted share units (RSUs) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated.
The RSUs are scheduled to vest on the date immediately preceding the conclusion of the next annual meeting of shareholders and will be settled in common shares. After this grant, Ross directly holds 85,233 common shares, indicating this is a routine annual equity award for a non-employee director rather than an open-market purchase.
ROBERTSON RUSSEL C reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp director Russel C. Robertson received an equity award rather than buying shares on the market. He was granted 15,842 common shares at $15.78 per share as part of his annual restricted share unit (RSU) grant for non-employee directors.
Following this grant, he directly holds 94,260 common shares. The RSUs are scheduled to vest immediately before the company’s next annual meeting of shareholders and will then be settled in common shares under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.
Bausch & Lomb Corp director John Paulson reported receiving a stock-based compensation award rather than making an open-market trade. He acquired 15,842 common shares at an accounting value of $15.78 per share through a grant of restricted share units under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.
Following this award, his direct holdings rose to 89,823 common shares. The RSUs are scheduled to vest on the date immediately preceding the conclusion of the next annual meeting of shareholders and will be settled in common shares when vested.
Ling Karen reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp director Karen Ling received an equity grant rather than buying shares on the market. She was awarded 15,842 common shares at a reference price of $15.78 per share as part of her annual restricted share unit (RSU) grant for non-employee directors. Following this award, she directly holds 61,518 common shares. The RSUs are scheduled to vest immediately before the conclusion of the next annual meeting of shareholders, when they will be settled in common shares.
KAVANAGH SARAH B reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp director Sarah B. Kavanagh received an equity grant of 15,842 common shares-equivalent on an award date price of $15.78 per share. The grant reflects annual restricted share units for non-employee directors under the company’s 2022 Omnibus Incentive Plan.
The RSUs are scheduled to vest immediately before the conclusion of the next annual meeting of shareholders and will be settled in common shares. Following this award, Kavanagh directly holds 69,541 common shares, highlighting this as compensation-related rather than an open-market purchase.
COLLIS STEVEN H reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp director Steven H. Collis received an equity award rather than buying shares on the market. He was granted 15,842 common-share-equivalent restricted share units (RSUs) valued at $15.78 per unit, bringing his direct holdings to 42,003 common shares after the award.
The RSUs were granted as the annual award to non-employee directors under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan. They are scheduled to vest on the date immediately before the company’s next annual meeting of shareholders, when they will be settled in common shares.
Bernier Nathalie D. reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp director Nathalie D. Bernier received an annual equity award in the form of restricted share units (RSUs). She was granted 15,842 common shares at a reference price of $15.78 per share, increasing her direct holdings to 85,505 common shares.
The footnote explains this is the regular annual RSU grant to non-employee directors under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan. These RSUs will vest immediately before the next annual meeting of shareholders and will then be settled in common shares.
Alfonso Eduardo reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp director Alfonso Eduardo received an equity award linked to 15,842 common shares of the company. The Form 4 shows this as a grant or award, not an open-market purchase, at a reference price of $15.78 per share. This reflects his annual grant of restricted share units under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan for non-employee directors. The RSUs will be settled in common shares and are scheduled to vest immediately before the conclusion of the next annual meeting of shareholders. Following this award, Eduardo directly holds 31,072 common shares.